Stable laquinimod preparations

US8545885B2 · kind B2 · utility

Assignees

• TEVA PHARMACEUTICAL INDUSTRIES, LTD. · IL
• Active Biotech AB · SE

Inventors

• Muhammad Safadi · Nazareth, IL
• Daniella Licht · Givat Shmuel, IL
• Ioana Lovinger · Kfar Sava, IL
• Aharon Eyal · Jerusalem, IL
• Tomas Fristedt · Helsingborg, SE
• Karl Jansson · Dalby, SE

Key dates

• Filing date: May 14, 2012
• Grant date: Oct 1, 2013
• Expiry date: May 14, 2032

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T436/145555
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3′-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.